Literature DB >> 9261421

Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV.

M E Waris1, C Tsou, D D Erdman, D B Day, L J Anderson.   

Abstract

To investigate enhanced disease associated with a formalin-inactivated (FI) respiratory syncytial virus (RSV) vaccine, we studied the pulmonary inflammatory response to RSV in BALB/c mice immunized with live RSV, FI-RSV, or combinations of the two. After RSV challenge, the number of granular cells, the ratio of CD4+/CD8+ lymphocytes, and the level of Th2-like cytokine mRNAs in the bronchoalveolar lavage specimens in mice immunized first with live RSV and then with FI-RSV were lower than that in FI-RSV-immunized mice and close to that in live RSV-immunized mice. These data suggest that prior live RSV infection prevents most of the enhanced inflammatory response seen in FI-RSV-immunized mice and might explain lack of enhanced disease in older FI-RSV-immunized children. A live RSV vaccine might similarly decrease the risk of enhanced disease with non-live RSV vaccines.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9261421      PMCID： PMC191977     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  14 in total

1.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

Authors:  J Chin; R L Magoffin; L A Shearer; J H Schieble; E H Lennette
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

2.  Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern.

Authors:  M E Waris; C Tsou; D D Erdman; S R Zaki; L J Anderson
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus.

Authors:  F Vaux-Peretz; B Meignier
Journal:  Vaccine       Date:  1990-12       Impact factor: 3.641

4.  Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

Authors:  M Connors; N A Giese; A B Kulkarni; C Y Firestone; H C Morse; B R Murphy
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 5.  An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines.

Authors:  B R Murphy; S L Hall; A B Kulkarni; J E Crowe; P L Collins; M Connors; R A Karron; R M Chanock
Journal:  Virus Res       Date:  1994-04       Impact factor: 3.303

6.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

7.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

8.  Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.

Authors:  M Connors; A B Kulkarni; C Y Firestone; K L Holmes; H C Morse; A V Sotnikov; B R Murphy
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

Authors:  B R Murphy; E E Walsh
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

10.  Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.

Authors:  B R Murphy; G A Prince; E E Walsh; H W Kim; R H Parrott; V G Hemming; W J Rodriguez; R M Chanock
Journal:  J Clin Microbiol       Date:  1986-08       Impact factor: 5.948
View more
  25 in total

1.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

2.  Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.

Authors:  U F Power; T Huss; V Michaud; H Plotnicky-Gilquin; J Y Bonnefoy; T N Nguyen
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

3.  Granulocyte-macrophage colony-stimulating factor expressed by recombinant respiratory syncytial virus attenuates viral replication and increases the level of pulmonary antigen-presenting cells.

Authors:  A Bukreyev; I M Belyakov; J A Berzofsky; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.

Authors:  A C Schmidt; J M McAuliffe; B R Murphy; P L Collins
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

5.  Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.

Authors:  R A Tripp; D Moore; L Jones; W Sullender; J Winter; L J Anderson
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

Review 6.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

7.  Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.

Authors:  Young-Man Kwon; Hye Suk Hwang; Jong Seok Lee; Eun-Ju Ko; Si-Eun Yoo; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Jae-Min Song; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2014-01-23       Impact factor: 5.970

8.  Live-attenuated respiratory syncytial virus vaccines.

Authors:  Ruth A Karron; Ursula J Buchholz; Peter L Collins
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

9.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

10.  Ginseng diminishes lung disease in mice immunized with formalin-inactivated respiratory syncytial virus after challenge by modulating host immune responses.

Authors:  Jong Seok Lee; Min Kyoung Cho; Hye Suk Hwang; Eun-Ju Ko; Yu-Na Lee; Young-Man Kwon; Min-Chul Kim; Ki-Hye Kim; Young-Tae Lee; Yu-Jin Jung; Sang-Moo Kang
Journal:  J Interferon Cytokine Res       Date:  2014-07-22       Impact factor: 2.607
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.